Point-of-Care Infectious Disease Diagnostics/Testing Market Analysis by Disease (HIV POC, HBV POC, Influenza/Flu POC, TB & drug-resistant TB POC), by End-use and Segment Forecasts, 2014 - 2025

  • ID: 4396355
  • Report
  • 145 pages
  • Grand View Research
1 of 4
The Global Point-of-Care Infectious Disease Diagnostics/Testing Market is Expected to Reach USD 1.90 Billion by 2025

FEATURED COMPANIES

  • Abbott
  • bioMérieux SA
  • Danaher
  • Hoffmann-La Roche Ltd
  • Quest Diagnostics Inc.
  • Sight Diagnostics Ltd
  • MORE
The global point-of-care infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in this market through to 2025.

For instance, development of a new ‘lab-on-a-disc’ technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

Further key findings from the report suggest:
  • HIV POC is estimated to account for the largest share owing to the rising incidence of this disease
  • Advances in the bio sensing technology for the early detection with sensitivity is expected to fuel revenue generation in the coming years
  • Moreover, companies are engaged in embracing a quality management approach for the introduction of novel tests for HIV diagnosis
  • TB and drug resistant TB is anticipated to witness lucrative demand in the coming years as a result of rise in the incidence rate of drug resistance TB
  • Demand for the development of inexpensive, rapid, simple, and accurate tests that are able to detect multiple biomarkers simultaneously is expected to boost progress
  • Implementation of fully or partially integrated nano/microscale technologies in developing DR-TB diagnostic devices is anticipated to fuel progress in the segment
  • Clinics accounted for the largest revenue share owing to the higher usage of rapid testing kits in clinics
  • North America dominates the space with adequate administration support, well-established healthcare framework, and extensive research & technology upgradation
  • Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support
  • The major players in the sector include Siemens Healthineers, Trivitron Healthcare, F. Hoffmann-La Roche Ltd, Alere, Quest Diagnostics, Inc, BD & Company, Chembio Diagnostics Inc,Trinity Biotech, Cardinal Health,Bio-Rad Labs Inc.,bioMérieux SA, Thermo Fisher Scientific Inc, Sight Diagnostics Ltd.,Gene POC, Ortho-Clinical Diagnostics, and OJ-Bio Ltd.


PLEASE NOTE:
This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • bioMérieux SA
  • Danaher
  • Hoffmann-La Roche Ltd
  • Quest Diagnostics Inc.
  • Sight Diagnostics Ltd
  • MORE

Chapter 1 Research Methodology
1.1 Information Procurement
1.1.1 Purchased Database
1.1.2 Internal database
1.2 Data Analysis
1.3 Market Formulation & Validation
1.4 Approaches for Market Estimation
1.4.1 Approach 1: Commodity Flow & Bottom Up Approach
1.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Point -of- Care Infectious Disease Diagnostics/Testing Market: Variables, Trends & Scope
3.1 Market Segmentation &Scope
3.1.1 Market driver analysis
3.1.1.1 Advancements in point of care diagnostics (POC) technology
3.1.1.2 Changes in healthcare reform to patient - centered care
3.1.1.3 Increasing demand for decentralized Infectious Disease Testing
3.1.1.4 Escalating rates of Infectious diseases
3.1.2 Market restraint analysis
3.1.2.1 Challenge of developing highly sensitive & accurate POC testing
3.1.2.2 Challenges related to consumer access and adoption
3.2 Penetration & Growth Prospect Mapping for Therapeutic Area, 2016
3.3 Point-Of-Care Infectious Disease Diagnostics/Testing Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s

Chapter 4 Point -of- Care Infectious Disease Diagnostics/Testing: Disease Estimates & Trend Analysis
4.1 Global Point-Of-Care Infectious Disease Diagnostics/Testing Market: Disease Movement Analysis
4.2 HIV POC
4.2.1 Global HIV POC, 2014 - 2025 (USD Million)
4.3 Clostridium difficile POC
4.3.1 Global clostridium difficile poc market, 2014 - 2025 (USD Million)
4.4 HBV POC
4.4.1 Global HBV POC market, 2014 - 2025 (USD Million)
4.5 Pneumonia or Streptococcus associated infections
4.5.1 Global Pneumonia or streptococcus associated infections market, 2014 - 2025 (USD Million)
4.6 Respiratory syncytial virus (RSV) POC
4.6.1 Global respiratory syncytial virus (RSV) POC market, 2014 - 2025 (USD Million)
4.7 HPV POC
4.7.1 Global HPV POC market, 2014 - 2025 (USD Million)
4.8 Influenza/Flu POC
4.8.1 Global influenza/flu POC market, 2014 - 2025 (USD Million)
4.9 HCV POC
4.9.1 Global HCV POC market, 2014 - 2025 (USD Million)
4.10 MRSA POC
4.10.1 Global MRSA POC market, 2014 - 2025 (USD Million)
4.11 TB and drug-resistant TB POC
4.11.1 Global TB and drug-resistant TB POC market, 2014 - 2025 (USD Million)
4.12 HSV POC
4.12.1 Global HSV POC market, 2014 - 2025 (USD Million)
4.13 Other infectious disease POC
4.13.1 Global other infectious disease POC market, 2014 - 2025 (USD Million)

Chapter 5 Point -of- Care Infectious Disease Diagnostics/Testing: End-Use Estimates & Trend Analysis
5.1 Global Point-Of-Care Infectious Disease Diagnostics/Testing market: End- Use Movement Analysis
5.2 Hospitals
5.2.1 Global hospitals market, 2014 - 2025 (USD Million)
5.3 Clinics
5.3.1 Global clinics market, 2014 - 2025 (USD Million)
5.4 Home
5.4.1 Global home market, 2014 - 2025 (USD Million)
5.5 Assisted Living Healthcare Facilities
5.5.1 Global assisted living healthcare facilities
5.6 Laboratories
5.6.1 Global laboratories market, 2014 - 2025 (USD Million)
5.7 Others
5.7.1 Global others market, 2014 - 2025 (USD Million)

Chapter 6 Point -of- Care Infectious Disease Diagnostics/Testing: Regional Estimates & Trend Analysis by Disease, & End-Use
6.1 Point-Of-Care Infectious Disease Diagnostics/Testing Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. point-of-care infectious disease diagnostics/testing market,by disease 2014 - 2025 (USD Million)
6.2.2.2 U.S. point-of-care infectious disease diagnostics/testing market,by end-use 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada point-of-care infectious disease diagnostics/testing market,by disease 2014 - 2025 (USD Million)
6.2.3.2 Canada point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
6.3.2 Germany
6.3.2.1 Germany point-of-care infectious disease diagnostics/testing market,by disease 2014 - 2025 (USD Million)
6.3.2.2 Germany point-of-care infectious disease diagnostics/testing market,by end-use 2014 - 2025 (USD Million)
6.3.3 UK
6.3.3.1 UK point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
6.3.3.2 UK point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
6.4.2.2 Japan point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
6.4.3.2 China point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
6.5.2.2 Brazil point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
6.6 Middle East & Africa (MEA)
6.6.1 Middle East & Africa point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa point-of-care infectious disease diagnostics/testing market,by disease 2014 - 2025 (USD Million)
6.6.2.2 South Africa point-of-care infectious disease diagnostics/testing market,by end-use 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.3 Company Profiles
7.3.1 Abbott
7.3.1.1 Company overview
7.3.1.2 Alere Inc.
7.3.1.3 Financial performance
7.3.1.4 Product benchmarking
7.3.1.5 Strategic initiatives
7.3.2 Bio-Rad Laboratories, Inc.
7.3.2.1 Company Overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Quest Diagnostics Inc.
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Thermo Fisher Scientific, Inc.
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Hoffmann-La Roche Ltd
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Danaher
7.3.6.1 Company overview
7.3.6.1.1 Beckman Coulter, Inc.
7.3.6.1.2 Cepheid
7.3.6.2 Company overview
7.3.6.3 Financial performance
7.3.6.4 Product benchmarking
7.3.6.5 Strategic initiatives
7.3.7 Siemens Healthineers
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 Sight Diagnostics Ltd
7.3.8.1 Company Overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
7.3.9 bioMérieux SA
7.3.9.1 Company Overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.9.4 Strategic initiatives
7.3.10 Cardinal Health
7.3.10.1 Company Overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives
7.3.11 Trinity Biotech
7.3.11.1 Company Overview
7.3.11.2 Financial performance
7.3.11.3 Product benchmarking
7.3.11.4 Strategic initiatives
7.3.12 Ortho Clinical Diagnostics
7.3.12.1 Company Overview
7.3.12.2 Financial performance
7.3.12.3 Product benchmarking
7.3.12.4 Strategic initiatives
7.3.13 Gene POC
7.3.13.1 Company Overview
7.3.13.2 Financial performance
7.3.13.3 Product benchmarking
7.3.13.4 Strategic initiatives
7.3.14 Becton Dickinson Company
7.3.14.1 Company Overview
7.3.14.2 Financial performance
7.3.14.3 Product benchmarking
7.3.14.4 Strategic initiatives
7.3.15 Trivitron Healthcare
7.3.15.1 Company Overview
7.3.15.2 Labsystems Diagnostics Oy
7.3.15.3 Financial performance
7.3.15.4 Financial performance
7.3.15.5 Product benchmarking
7.3.15.6 Strategic initiatives
7.3.16 Chembio Diagnostics Systems, Inc
7.3.16.1 Company Overview
7.3.16.2 Financial performance
7.3.16.3 Product benchmarking
7.3.16.4 Strategic initiatives
7.3.17 OJ-Bio Ltd
7.3.17.1 Company Overview
7.3.17.2 Financial performance
7.3.17.3 Product benchmarking
7.3.17.4 Strategic initiatives

List of Tables
Table 1 Proportion of MDR TB in high-burden countries in 2015
Table 2 North America point-of-care infectious disease diagnostics/testing market, by disease, 2014 - 2025 (USD Million)
Table 3 North America point-of-care infectious disease diagnostics/testing market, by end-use, 2014 - 2025 (USD Million)
Table 4 U.S. point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 5 U.S. point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 6 Canada point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 7 Canada point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 8 Europe point-of-care infectious disease diagnostics/testing market, by disease, 2014 - 2025 (USD Million)
Table 9 Europe point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 10 Germany point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 11 Germany point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 12 UK point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 13 UK Point-Of-Care Infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 14 Asia Pacific point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 15 Asia Pacific point-of-care infectious disease diagnostics/testing market, by end-use, 2014 - 2025 (USD Million)
Table 16 Japan point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 17 Japan point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 18 China point-of-care infectious disease diagnostics/testing market, by disease 2014 - 2025 (USD Million)
Table 19 China point-of-care infectious disease diagnostics/testing market, by end-use 2014 - 2025 (USD Million)
Table 20 Latin America point-of-care infectious disease diagnostics/testing market, by disease, 2014 - 2025 (USD Million)
Table 21 Latin America point-of-care infectious disease diagnostics/testing market, by end use, 2014 - 2025 (USD Million)
Table 22 Brazil point-of-care infectious disease diagnostics/testing market, by disease, 2014 - 2025 (USD Million)
Table 23 Brazil point-of-care infectious disease diagnostics/testing market, by end-use, 2014 - 2025 (USD Million)
Table 24 Middle East & Africa (MEA) point-of-care infectious disease diagnostics/testing market, by disease, 2014 - 2025 (USD Million)
Table 25 Middle East & Africa (MEA) point-of-care infectious disease diagnostics/testing market, by end-use, 2014 - 2025 (USD Million)
Table 26 South Africa point-of-care infectious disease diagnostics/testing market, by disease, 2014 - 2025 (USD Million)
Table 27 South Africa point-of-care infectious disease diagnostics/testing market, by end-use, 2014 - 2025 (USD Million)

List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping for workflow, 2016
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Global point-of-care infectious disease diagnostics/testing market: Disease type outlook key takeaways
FIG. 16 Global point-of-care infectious disease diagnostics/testing market: Disease type movement analysis
FIG. 17 Global target identification & screening market, 2014 - 2025 (USD Million)
FIG. 18 Global clostridium difficile poc market, 2014 - 2025 (USD Million)
FIG. 19 Global HBV POC market, 2014 - 2025 (USD Million)
FIG. 20 Global pneumonia or streptococcus associated infections market, 2014 - 2025 (USD Million)
FIG. 21 Global respiratory syncytial virus (RSV) POC market, 2014 - 2025 (USD Million)
FIG. 22 Global HPV POC market, 2014 - 2025 (USD Million)
FIG. 23 Global influenza/flu POC market, 2014 - 2025 (USD Million)
FIG. 24 Global HCV POC market, 2014 - 2025 (USD Million)
FIG. 25 Global MRSA POC market, 2014 - 2025 (USD Million)
FIG. 26 Global TB and drug-resistant TB POC market, 2014 - 2025 (USD Million)
FIG. 27 Global HSV POC market, 2014 - 2025 (USD Million)
FIG. 28 Global other infectious disease POC market, 2014 - 2025 (USD Million)
FIG. 29 Global point-of-care infectious disease diagnostics/testing market: End -use estimates outlook key takeaways
FIG. 30 Global point-of-care infectious disease diagnostics/testing market: Therapeutic Area movement analysis
FIG. 31 Global hospitals and clinics market, 2014 - 2025 (USD Million)
FIG. 32 Global clinics market, 2014 - 2025 (USD Million)
FIG. 33 Global home market, 2014 - 2025 (USD Million)
FIG. 34 Global assisted living healthcare facilities
FIG. 35 Global laboratories market, 2014 - 2025 (USD Million)
FIG. 36 Global others market, 2014 - 2025 (USD Million)
FIG. 37 Regional market place: Key takeaway
FIG. 38 Point-of-care infectious disease diagnostics/testing market regional outlook, 2016 & 2025
FIG. 39 North America point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 40 U.S. point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 41 Canada point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 42 Europe point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 43 Germany point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 44 UK point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 45 Asia Pacific point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 46 Japan point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 47 China point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 48 Latin America point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 49 Brazil point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 50 Middle East & Africa point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 51 South Africa point-of-care infectious disease diagnostics/testing market, 2014 - 2025 (USD Million)
FIG. 52 Strategy framework

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott
  • Bio-Rad Laboratories, Inc.
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific, Inc.
  • Hoffmann-La Roche Ltd
  • Danaher
  • Siemens Healthineers
  • Sight Diagnostics Ltd
  • bioMérieux SA
  • Cardinal Health
  • Trinity Biotech
  • Ortho Clinical Diagnostics
  • Gene POC
  • Becton Dickinson Company
  • Trivitron Healthcare
  • Chembio Diagnostics Systems, Inc
  • OJ-Bio Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll